原发性肝细胞癌经动脉内用药与联合用药中国专家共识

Chinese expert consensus on intra-arterial drug and combined drug administration for primary hepatocellular carcinoma

经动脉介入治疗是原发性肝细胞癌中应用最广泛的治疗方式之一,随着介入技术的进步和新兴药物的使用,在原发性肝细胞癌的治疗上取得了较好的疗效,已成为中晚期肝癌首选的非手术治疗方法。但目前经动脉介入治疗中所用的药物及与其他药物的联合应用方案各中心存在较大差异,并无统一的共识或指南。基于此,中国医师协会介入医师分会介入药物专业组组织专家依据国内外最新研究数据和临床实践经验,结合我国患者的特点制订有关原发性肝细胞癌经动脉内用药与联合用药中国专家共识,旨在探讨经动脉介入治疗相关药物和联合用药的疗效与安全性、使用方法、特殊人群用药、不良反应管理以及辅助用药等,供临床实践参考。

Transarterial interventional therapy is one of the most widely used treatment methods in patients with primary hepatocellular carcinoma.With the progress in interventional technology and the use of new drugs,transarterial interventional therapy has achieved favorable results in the treatment of primary hepatocellular carcinoma and has become the first choice non-surgical treatment for advanced liver cancer.However,at present,there are great differences in the drugs used in transarterial interventional treatment and the combined application of other drugs among centers,and there is no uniform consensus or guideline.Based on the latest research data and clinical practice experience,as well as the characteristics of Chinese patients,the Specialist Group of Interventional Drugs,Interventionalists Branch of the Chinese Medical Doctor Association was organized to formulate the Chinese expert consensus on intra-arterial drug and combined drug administration for primary hepatocellular carcinoma.The purpose of this consensus is to explore the efficacy and safety of drugs and drug combinations related to intra-arterial interventional therapy,the use of drugs in special populations,the management of adverse reactions,and adjuvant drugs to provide a reference for clinical practice.